{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:22:54Z","timestamp":1782602574800,"version":"3.54.5"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T00:00:00Z","timestamp":1154563200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> The current understanding of dialysis\u2010related amyloidosis has evolved over the past two decades. In the early 1980s, several researchers found amyloid deposits in the synovia of carpal tunnel syndrome (CTS), which have been recognized as a complication of chronic hemodialysis. The enigma was resolved in 1985, when \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin (\u03b2<jats:sub>2<\/jats:sub>\u2010m) with a molecular weight of 12\u2003000\u2003Da was identified as the major constitutional protein of this amyloid. Amyloid fibrils of this type that contain the sub\u2010unit protein of human leukocyte antigens (HLA), \u03b2<jats:sub>2<\/jats:sub>\u2010m, deposit predominantly in osteoarticular tissues, inducing musculoskeletal symptoms such as CTS, polyarthralgia, bone cyst showing radiolucency at X\u2010ray examination and destructive spondyloarthropathy. In addition, extra articular symptoms such as ischemic colitis, megaloglossia, and heart failure, that is, systemic involvement occasionally occur. We confirmed that the prevalence of CTS increases with duration of dialysis. Most patients with CTS associated with \u03b2<jats:sub>2<\/jats:sub>\u2010m amyloid deposits have undergone hemodialysis for 10\u2003years or more. Up to 50% of patients had developed this complication after 20\u2003years and the percentage was even higher after 25\u2003years. General categories of therapeutic approaches for amyloidosis include prevention of onset or progression, symptomatic therapy (conservative treatment, orthopedic procedures, and physiotherapy), and renal transplantation. It is critical to elucidate the detail mechanisms of the amyloid fibril formation, and establish its radical treatment. It is also important to develop novel therapies such as cell implantation to compensate for normal kidney functions of uremic toxin protein metabolism.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2006.00383.x","type":"journal-article","created":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T09:36:12Z","timestamp":1154597772000},"page":"316-320","source":"Crossref","is-referenced-by-count":43,"title":["Current Clinical Aspects of Dialysis\u2010Related Amyloidosis in Chronic Dialysis Patients"],"prefix":"10.1111","volume":"10","author":[{"given":"Akihiko","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitake","family":"Gejyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,8,3]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(85)91948-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186832"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602273140920"},{"key":"e_1_2_7_5_2","first-page":"S75","article-title":"Apolipoprotein E and alpha 1\u2010antichymotrypsin in dialysis\u2010related amyloidosis","volume":"62","author":"Gejyo F","year":"1997","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/13506120209114819"},{"key":"e_1_2_7_7_2","first-page":"104","article-title":"Kinetic analysis of amyloid fibril polymerization in vitro","volume":"65","author":"Naiki H","year":"1991","journal-title":"Lab Invest"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi0027128"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000103228.81623.C7"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi049262u"},{"issue":"9","key":"e_1_2_7_11_2","first-page":"S7","article-title":"Protein constituents of amyloid deposits in beta 2\u2010microglobulin amyloidosis","volume":"61","author":"Garc\u00eda\u2010Garc\u00eda M","year":"1994","journal-title":"Rev Rhum"},{"key":"e_1_2_7_12_2","first-page":"243","article-title":"A monoclonal antibody recognizing apolipoprotein E peptides in systemic amyloid deposits","volume":"24","author":"Yamada T","year":"1994","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/clinchem\/36.1.88","article-title":"Glycosaminoglycans of the hemodialysis\u2010associated carpal synovial amyloid and of amyloid\u2010rich tissues and fibrils of heart, liver, and spleen","volume":"36","author":"Ohishi H","year":"1990","journal-title":"Clin Chem"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00203737"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117002"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00167.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186986"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6677.867"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1991.128"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186764"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.supp7.7"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.1993.tb00574.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.2004.47260.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000078804.98322.4A"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000062962.51879.F8"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0074"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2006.00383.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2006.00383.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T14:06:12Z","timestamp":1697292372000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2006.00383.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1744-9987.2006.00383.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2006.00383.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}